Pfizer signs deal to manufacture Gilead's remdesivir for COVID-19
Pfizer Inc said on Friday it signed a multi-year agreement to manufacture Gilead Sciences Inc's antiviral drug remdesivir for COVID-19 patients in a bid to ramp up its supply. The company would use its Kansas plant to manufacture the drug, it said.
- Country:
- United States
Pfizer Inc said on Friday it signed a multi-year agreement to manufacture Gilead Sciences Inc's antiviral drug remdesivir for COVID-19 patients in a bid to ramp up its supply.
The company would use its Kansas plant to manufacture the drug, it said. The drug is one of only two that have demonstrated an ability to help hospitalized COVID-19 patients in formal clinical trials.
On Thursday, Gilead said its manufacturing network for the drug had grown to more than 40 companies in North America, Europe and Asia to add capacity. Britain's Hikma Pharmaceuticals has started manufacturing remdesivir at its Portugal plant, the British company's chief executive officer said on Friday.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
GLOBAL MARKETS-Nikkei leads Asia higher as yen skids; commodities in demand
MORNING BID EUROPE-Yen down on everything but the dollar
GLOBAL MARKETS-Nikkei leads Asia higher as yen slips; commodities on a roll
Southeast Asian countries consider ways to boost 'green financing' as region chokes on smog
US needs Europe for its security too, NATO chief says
Google News